{'fraction_non_alphanumeric': 0.04685622747296756, 'fraction_numerical': 0.06087304765718863, 'mean_word_length': 5.0048076923076925, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Increasing prevalence but not incidence of psoriasis in the U.K.

and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64:1035–50. 3 Sorenson E, Koo J. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: providing clarity to an opaque topic. J Dermatolog Treat 2015; 26:493–501. 4 Michaud TL, Rho YH, Shamliyan T et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a metaanalysis update of 44 trials. Am J Med 2014; 127:1208–32. 5 Sehgal VN, Pandhi D, Khurana A. Biologics in dermatology: adverse effects. Int J Dermatol 2015; 54:1442–60. 6 Kirsten N, Bulai Livideanu C, Richard MA et al.; French Psoriasis Research Group. Inclusion and exclusion criteria in phase III trials with systemic agents in psoriasis: the external validity of drug development. Br J Dermatol 2016; 175:636–8. 7 Garc ıa-Doval I, Carretero G, Vanaclocha F et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148:463–70. 8 Girolomoni G, Altomare G, Ayala F et al. Safety of anti-TNFa agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol Immunotoxicol 2012; 34:548–60. 9 Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012; 167(Suppl. 3):3–11. 10 Carretero G, Ferrandiz C, Dauden E et al.; BIOBADADERM Study Group. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008–2013 results of the BIOBADADERM registry. J Eur Acad Dermatol Venereol 2015; 29:156–63. 11 Kalb RE, Fiorentino DF, Lebwohl MG et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the PSOriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol 2015; 151:961–9. 12 Garc ıa-Doval I, Hern andez MV, Vanaclocha F et al.; BIOBADADERM and BIOBADASER study groups. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol 2017; 176:643–49.